View Future GrowthCharming Medical 過去の業績過去 基準チェック /36Charming Medicalは、平均年間54.2%の収益成長を遂げていますが、 Consumer Services業界の収益は、年間 成長しています。収益は、平均年間25.6% 3.4%収益成長率で 成長しています。 Charming Medicalの自己資本利益率は2435%であり、純利益率は19.3%です。主要情報54.16%収益成長率54.16%EPS成長率Consumer Services 業界の成長20.27%収益成長率3.43%株主資本利益率2,435.04%ネット・マージン19.27%前回の決算情報31 Mar 2025最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Mar 28Charming Medical Limited Announces Resignation of Independent Director Josephine Yan Yeung, Effective March 27, 2026Charming Medical Limited announced that on March 27, 2026, Ms. Josephine Yan Yeung notified the Company of her resignation as an independent director, effective March 27, 2026, in order to pursue other business commitments. On March 27, 2026, the Board of Directors of the Company accepted and approved Ms. Yeung's resignation. The Company is in the process of identifying a suitable replacement and expects to fill the vacancy by April 2, 2026.お知らせ • Jan 08Charming Medical Limited Announces Board ChangesCharming Medical Limited on December 23, 2025, Mr. Leut Ming Gung notified the Company of his resignation as an independent director, effective December 31, 2025, in order to pursue other business commitments. Mr. Gung’s resignation was not a result of any disagreement with the Company’s operations, policies, or procedures. On January 5, 2026, the Board of Directors of the Company accepted and approved Mr. Gung’s resignation. On January 5, 2026, the Board of Directors, Nominating Committee, and the Compensation Committee approved by resolutions and confirmed the appointment of Mr. Yin Jiang as a director of the Company, with an annual compensation of HKD 240,000, effective upon approval of the resolutions, until his successor is duly elected and qualified, or until his earlier death, resignation or removal. The Board has determined Mr. Jiang is an “independent” director under applicable U.S. Securities and Exchange Commission and Nasdaq Marketplace Rules. Mr. Jiang will be serving on the Board of Directors as a non-employee, independent director. Mr. Jiang has also been named as the chairman of the Compensation Committee and a member of the Audit Committee and Nominating Committee of the Company. Mr. Jiang has been involved in fund management activities since 2016. In 2017, he founded Panshi Capital, a private equity fund, which was acquired in 2019 by a multi-billion RMB institution in China. He also has experience in artificial intelligence and blockchain technologies and holds multiple invention patents and software copyrights in these fields. In 2013, Mr. Jiang founded Panzhong Technology Co. Ltd., a technology company focused on fiber-optic communication and high-performance computing applications. From 2004 to 2013, he served as a software test engineer at Cisco WebEx. Mr. Jiang received a Bachelor of Science degree in Applied Physics from the University of Science and Technology of China in 2004 and holds a securities investment fund qualification certificate issued by the Asset Management Association of China.お知らせ • Dec 20Robbins LLP Informs Investors of the Charming Medical, Limited Securities Class ActionRobbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Charming Medical, Limited securities between October 10, 2025 and November 12, 2025. The Company claims to "enhance the quality of life from the inside out by integrating Traditional Chinese Medicine (TCM) wellness practices with modern technology." The Allegations: Robbins LLP is Investigating Allegations that Charming Medical, Limited (MCTA) Engaged in a Fraudulent Stock Promotion Scheme. According to the complaint, defendants failed to disclose that: (1) Charming was the subject of a fraudulent stock promotion scheme involving social media based misinformation and impersonated financial professionals; (2) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; and (3) Charming's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price. Plaintiff alleges that in the weeks leading up to November 12, 2025, Charming's share price surged from the initial public offering price of $4.00 to an all-time high of $29.36 per share, despite no fundamental news from the Company justifying such a spike. Investigations and public reports have revealed that Charming's stock became the subject of an illicit social-media-based promotion scheme that artificially inflated its price. These reports detail how impersonators claiming to be legitimate financial advisors touted Charming in online forums, chat groups, and through social media posts with sensational, but baseless, claims to create a buying frenzy among retail investors. On November 12, 2025, the SEC halted trading of Charming's stock. The stock remains halted because the Company has not provided the information regulators required to lift the suspension.Board Change • Oct 22High number of new directorsIndependent Director Josephine Yeung was the last director to join the board, commencing their role in 2025.お知らせ • Oct 21Charming Medical Limited has completed an IPO in the amount of $6.4 million.Charming Medical Limited has completed an IPO in the amount of $6.4 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 1,600,000 Price\Range: $4 Discount Per Security: $0.28収支内訳Charming Medical の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:MCTA 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 25614031 Dec 24614030 Sep 24614030 Jun 24614031 Mar 24614031 Mar 234040質の高い収益: MCTAは 高品質の収益 を持っています。利益率の向上: MCTAの現在の純利益率 (19.3%)は、昨年(12.9%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: MCTAの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: MCTAの過去 1 年間の収益成長を 5 年間の平均と比較するにはデータが不十分です。収益対業界: MCTAの過去 1 年間の収益成長率 ( 54.2% ) はConsumer Services業界9.1%を上回りました。株主資本利益率高いROE: MCTAの 自己資本利益率 ( 2435.04% ) は 抜群 ですが、負債レベルが高いためこの指標は歪んでいます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YConsumer-services 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/08 15:36終値2025/11/11 00:00収益2025/03/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Charming Medical Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 28Charming Medical Limited Announces Resignation of Independent Director Josephine Yan Yeung, Effective March 27, 2026Charming Medical Limited announced that on March 27, 2026, Ms. Josephine Yan Yeung notified the Company of her resignation as an independent director, effective March 27, 2026, in order to pursue other business commitments. On March 27, 2026, the Board of Directors of the Company accepted and approved Ms. Yeung's resignation. The Company is in the process of identifying a suitable replacement and expects to fill the vacancy by April 2, 2026.
お知らせ • Jan 08Charming Medical Limited Announces Board ChangesCharming Medical Limited on December 23, 2025, Mr. Leut Ming Gung notified the Company of his resignation as an independent director, effective December 31, 2025, in order to pursue other business commitments. Mr. Gung’s resignation was not a result of any disagreement with the Company’s operations, policies, or procedures. On January 5, 2026, the Board of Directors of the Company accepted and approved Mr. Gung’s resignation. On January 5, 2026, the Board of Directors, Nominating Committee, and the Compensation Committee approved by resolutions and confirmed the appointment of Mr. Yin Jiang as a director of the Company, with an annual compensation of HKD 240,000, effective upon approval of the resolutions, until his successor is duly elected and qualified, or until his earlier death, resignation or removal. The Board has determined Mr. Jiang is an “independent” director under applicable U.S. Securities and Exchange Commission and Nasdaq Marketplace Rules. Mr. Jiang will be serving on the Board of Directors as a non-employee, independent director. Mr. Jiang has also been named as the chairman of the Compensation Committee and a member of the Audit Committee and Nominating Committee of the Company. Mr. Jiang has been involved in fund management activities since 2016. In 2017, he founded Panshi Capital, a private equity fund, which was acquired in 2019 by a multi-billion RMB institution in China. He also has experience in artificial intelligence and blockchain technologies and holds multiple invention patents and software copyrights in these fields. In 2013, Mr. Jiang founded Panzhong Technology Co. Ltd., a technology company focused on fiber-optic communication and high-performance computing applications. From 2004 to 2013, he served as a software test engineer at Cisco WebEx. Mr. Jiang received a Bachelor of Science degree in Applied Physics from the University of Science and Technology of China in 2004 and holds a securities investment fund qualification certificate issued by the Asset Management Association of China.
お知らせ • Dec 20Robbins LLP Informs Investors of the Charming Medical, Limited Securities Class ActionRobbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Charming Medical, Limited securities between October 10, 2025 and November 12, 2025. The Company claims to "enhance the quality of life from the inside out by integrating Traditional Chinese Medicine (TCM) wellness practices with modern technology." The Allegations: Robbins LLP is Investigating Allegations that Charming Medical, Limited (MCTA) Engaged in a Fraudulent Stock Promotion Scheme. According to the complaint, defendants failed to disclose that: (1) Charming was the subject of a fraudulent stock promotion scheme involving social media based misinformation and impersonated financial professionals; (2) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; and (3) Charming's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price. Plaintiff alleges that in the weeks leading up to November 12, 2025, Charming's share price surged from the initial public offering price of $4.00 to an all-time high of $29.36 per share, despite no fundamental news from the Company justifying such a spike. Investigations and public reports have revealed that Charming's stock became the subject of an illicit social-media-based promotion scheme that artificially inflated its price. These reports detail how impersonators claiming to be legitimate financial advisors touted Charming in online forums, chat groups, and through social media posts with sensational, but baseless, claims to create a buying frenzy among retail investors. On November 12, 2025, the SEC halted trading of Charming's stock. The stock remains halted because the Company has not provided the information regulators required to lift the suspension.
Board Change • Oct 22High number of new directorsIndependent Director Josephine Yeung was the last director to join the board, commencing their role in 2025.
お知らせ • Oct 21Charming Medical Limited has completed an IPO in the amount of $6.4 million.Charming Medical Limited has completed an IPO in the amount of $6.4 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 1,600,000 Price\Range: $4 Discount Per Security: $0.28